Eli Lilly seeks new angle on high-value target, tapping Oblique for antibody discovery push

Eli Lilly has expanded its partnership with Oblique Therapeutics, adding a second strand to an alliance focused on using the AbiProt platform to discover antibodies against high-value targets.